Dr. Mier is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Beth Israel Med Center
330 Brookline Ave
Boston, MA 02215Phone+1 617-667-0430
Education & Training
Emory University School of MedicineResidency, Internal Medicine, 1973 - 1975
Indiana University School of MedicineClass of 1973
Certifications & Licensure
MA State Medical License 1980 - 2021
GA State Medical License 1974 - 1977
Clinical Trials
- A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors Start of enrollment: 2012 Oct 01
- A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01
- Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors Start of enrollment: 2017 Feb 28
Publications & Presentations
PubMed
- 2 citationsRapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitorsRohit Thummalapalli, Johannes C. Melms, James W. Mier, Benjamin Izar
Melanoma Research. 2020-04-01 - 313 citationsLenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial CancerVicky Makker, Matthew H. Taylor, Carol Aghajanian, Ana Oaknin, James W. Mier
Journal of Clinical Oncology. 2020-03-13 - 17 citationsCXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors.Ruchi Saxena, Yan Wang, James W. Mier
Melanoma Research. 2020-02-01
Press Mentions
DF/HCC Kidney Cancer Program Symposium 2016May 20th, 2016
Grant Support
- P4 - Treating The P13-Kinase/AktNational Cancer Institute2010–2011
- Targeting RAF In Melanoma: Mechanisms For Effect &Resistance &Opportunities ForNational Cancer Institute2008–2011
- Treating The P13-Kinase/AktNational Cancer Institute2009
- Phase I Clinical Trial Of Decitabine Prior To Dacarbazine In Advanced MelanomaNational Center For Research Resources2005–2006
- Core--Immune MonitoringNational Cancer Institute2001–2002
- Clinical Trials With IL12National Cancer Institute2001–2002
- In Vivo Effects Of IL 2--Role Of TNF And TNF R FamiliesNational Cancer Institute1997–1999
- Immunobiology Of LAK CellsNational Cancer Institute1997–1998
- Biological Effects Of Rhil-12National Cancer Institute1997–1998
- Immunobiology Of LAK CellsNational Cancer Institute1987–1996
- Immunobiology Of LAK CellsNational Cancer Institute1991–1993
- In Vivo Effects Of Recombinant Human InterleukinNational Cancer Institute1985–1987
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
